Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.

JCO precision oncology - 1 Nov 2021

Sinha Neelam, Sinha Sanju, Cheng Kuoyuan, Madan Sanna, Erez Ayelet, Ryan Bríd M, Schäffer Alejandro A, Aldape Kenneth, Ruppin Eytan

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Immune Checkpoint Inhibitors
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Patient Selection

Source

Open in PubMed Open full text

Identifiers

PMID: 34994632
DOI: 10.1200/PO.21.00168
PMCID: PMC9848582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.PMID 34994632Read ↗

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicSemantic proximity Read ↗

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex biasSemantic proximity Read ↗

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?Semantic proximity Read ↗

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.Semantic proximity Read ↗

Tumor mutational load predicts survival after immunotherapy across multiple cancer typesSemantic proximity Read ↗

Tumor Mutation Burden and Cancer Treatment.Semantic proximity Read ↗

The status of tumor mutational burden and immunotherapySemantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.Semantic proximity Read ↗

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.